Cited by 171

The DOI matches its Crossref record.

Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells

Christopherson, Kent W., Cooper, Scott, Broxmeyer, Hal E.·2003·Blood

Abstract

CXC ligand 12 (CXCL12; also known as stromal cell–derived factor 1α/SDF-1α) chemoattracts hematopoietic stem and progenitor cells (HSCs/HPCs) and is thought to play a crucial role in the mobilization of HSCs/HPCs from the bone marrow. CD26 (dipeptidylpeptidase IV [DPPIV]) is a membrane-bound extracellular peptidase that cleaves dipeptides from the N-terminus of polypeptide chains. CD26 has the ability to cleave CXCL12 at its position-2 proline. We found by flow cytometry that CD26 is expressed on a subpopulation of normal Sca-1+c-kit+lin— hematopoietic cells isolated from mouse bone marrow, as well as Sca-1+c-kit—lin— cells, and that these cells possess CD26 peptidase activity. To test the functional role of CD26 in CXCL12-mediated normal HSC/HPC migration, chemotaxis assays were performed. The CD26 truncated CXCL12(3-68) showed an inability to induce the migration of sorted Sca-1+c-kit+lin— or Sca-1+c-kit—lin— mouse marrow cells compared with the normal CXCL12. In addition, CXCL12(3-68) acts as an antagonist, resulting in the reduction of migratory response to normal CXCL12. Treatment of Sca-1+c-kit+lin— mouse marrow cells, and myeloid progenitors within this population, or Sca-1+c-kit—lin— cells with a specific CD26 inhibitor, enhanced the migratory response of these cells to CXCL12. Finally, to test for potential in vivo relevance of these in vitro observations, mice were treated with CD26 inhibitors during granulocyte colony-stimulating factor (G-CSF)–induced mobilization. This treatment resulted in a reduction in the number of progenitor cells in the periphery as compared with the G-CSF regimen alone. This suggests that a mechanism of action of G-CSF mobilization involves CD26.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2002-12-3893

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 46

  1. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997;185: 111-120. · DOI · Paper page
  2. Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 1998;91: 100-110. · DOI
  3. Broxmeyer HE. Regulation of hematopoiesis by chemokine family members. Int J Hematol. 2001; 74: 9-17. · DOI
  4. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382: 635-638. · DOI
  5. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393: 595-599. · DOI
  6. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 1998; 95: 9448-9453. · DOI
  7. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998; 393: 591-594. · DOI
  8. Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta. 1992;1122: 147-153. · DOI
  9. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392: 565-568. · DOI
  10. Pal R, Garzino-Demo A, Markham PD, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science. 1997;278: 695-698. · DOI
  11. Struyf S, Proost P, Sozzani S, et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol. 1998;161: 2672-2675. · DOI
  12. Struyf S, De Meester I, Scharpe S, et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol. 1998;28: 1262-1271. · DOI
  13. Wuyts A, Govaerts C, Struyf S, et al. Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur J Biochem. 1999;260: 421-429. · DOI
  14. Tensen CP, Flier J, Van Der Raaij-Helmer EM, et al. Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol. 1999;112: 716-722. · DOI
  15. Noso N, Bartels J, Mallet AI, Mochizuki M, Christophers E, Schroder JM. Delayed production of biologically active O-glycosylated forms of human eotaxin by tumor-necrosis-factor-alpha-stimulated dermal fibroblasts. Eur J Biochem. 1998; 253: 114-122. · DOI
  16. Vulcano M, Albanesi C, Stoppacciaro A, et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol. 2001;31: 812-822. · DOI
  17. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med. 1997;186: 1865-1872. · DOI
  18. Schols D, Proost P, Struyf S, et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res. 1998; 39: 175-187. · DOI
  19. Proost P, De Meester I, Schols D, et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem. 1998;273: 7222-7227. · DOI
  20. Proost P, Struyf S, Schols D, et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett. 1998;432: 73-76. · DOI
  21. Shioda T, Kato H, Ohnishi Y, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A. 1998;95: 6331-6336. · DOI
  22. Van Coillie E, Proost P, Van Aelst I, et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry. 1998;37: 12672-12680. · DOI
  23. Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 1999;162: 4903-4909. · DOI
  24. Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999; 274: 3988-3993. · DOI
  25. Iwata S, Yamaguchi N, Munakata Y, et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol. 1999;11: 417-426. · DOI
  26. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood. 2000;96: 1674-1680. · DOI
  27. Lambeir AM, Proost P, Durinx C, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 2001;276: 29839-29845. · DOI
  28. Mentlein R. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept. 1999;85: 9-24. · DOI
  29. Vanham G, Kestens L, De Meester I, et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr. 1993;6: 749-757.
  30. Kahne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med. 1999;4: 3-15. · DOI
  31. Huhn J, Ehrlich S, Fleischer B, von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett. 2000;72: 127-132. · DOI
  32. Durinx C, Lambeir AM, Bosmans E, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000;267: 5608-5613. · DOI
  33. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989;86: 3828-3832. · DOI
  34. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321: 1174-1178. · DOI
  35. Broxmeyer H, Smith F. Cord blood stem cell transplantation. In: Thomas ED, ed. Hematopoietic Cell Transplantation 2nd ed. Oxford, United Kingdom; Blackwell Science; 1999: 431-443.
  36. Christopherson KW II, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002; 169: 7000-7008. · DOI · Paper page
  37. Christopherson KW II, Campbell JJ, Hromas RA. Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration. Blood. 2001;98: 3562-3568. · DOI
  38. Kojima K, Hama T, Kato T, Nagatsu T. Rapid chromatographic purification of dipeptidyl peptidase IV in human submaxillary gland. J Chromatogr. 1980;189: 233-240. · DOI
  39. Nagatsu T, Hino M, Fuyamada H, Hayakawa T, Sakakibara S. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. Anal Biochem. 1976;74: 466-476. · DOI
  40. Christopherson K II, Brahmi Z, Hromas R. Regulation of naive fetal T-cell migration by the chemokines Exodus-2 and Exodus-3. Immunol Lett. 1999;69: 269-273. · DOI
  41. Broxmeyer HE, Cooper S, Hangoc G, Gao JL, Murphy PM. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J Exp Med. 1999;189: 1987-1992. · DOI
  42. Cooper S, Broxmeyer HE. Measurement of inter-leukin-3 and other hematopoietic growth factors, such as GM-CSF, G-CSF, M-CSF, erythropoietin and the potent co-stimulating cyktokines steel factor and FLt-3 ligand. In: Coligan JE KA, Margulies DH, Shevach EM, Strober E, Coico R, eds. Current Protocols in Immunology. New York, NY: John Wiley & Sons; 1996: 6.4.1-6.4.12.
  43. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283: 845-848. · DOI · Paper page
  44. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3: 687-694. · DOI
  45. Roberts AW, Foote S, Alexander WS, Scott C, Robb L, Metcalf D. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood. 1997;89: 2736-2744. · DOI
  46. Hasegawa M, Baldwin TM, Metcalf D, Foote SJ. Progenitor cell mobilization by granulocyte colony-stimulating factor controlled by loci on chromosomes 2 and 11. Blood. 2000;95: 1872-1874. · DOI

Cited by

Metadata

Authors
Christopherson, K. W., Cooper, S., & Broxmeyer, H. E.
Affiliations
From the Department of Microbiology/Immunology and the Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN; and the Walther Cancer Institute, Indianapolis, IN.
Venue
Blood
Published
2003-06-15
Volume
101
Issue
12
Pages
4680-4686
ISSN
  • 0006-4971
  • 1528-0020
Cited by
171
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review